Various immune-checkpoint inhibitors are approved as adjuvant therapies for high-risk melanoma (stage IIB–IV), but disease recurrence remains common. Now, new data indicate that the personalized therapeutic vaccine mRNA-4157 (V940) improves disease control when added to adjuvant pembrolizumab.

中文翻译：

---

个性化新抗原 mRNA 疫苗可减轻黑色素瘤复发

各种免疫检查点抑制剂被批准作为高危黑色素瘤（IIB-IV 期）的辅助疗法，但疾病复发仍然很常见。现在，新数据表明，个性化治疗疫苗 mRNA-4157 (V940) 添加到佐剂派姆单抗中可改善疾病控制。